臨床分析化学/薬品分析化学/基礎分析化学/物理系実習/薬剤学実習/特別実習

研究テーマ

1. 凝固線溶系の中枢での役割
2. 薬物の有害事象改善の研究
3. 虚血・腫瘍における内皮細胞の役割
4. 民間薬の薬効評価
5. 基礎から臨床への橋渡し的研究

研究論文

1. Suzuki Y, Okamoto K, Sakamoto N, Kanomata C, Ohta S. The effects of febuxostat and allopurinol castration-resistant prostate cancer cells using CD44 as an indicator: Possibility for the drug repurposing of febuxostat in castration-resistant prostate cancer. Therapeutic Research. 44 (5), 363-366, 2023.
2. Suzuki Y, Deguchi M, Furuya A, Kato S, Ohta S. Febuxostat attenuates the induction of vascular cell adhesion protein 1 by TNF-α in Human Umbilical Vein Endothelial Cells. Pharmacology. 160 (3-4), 218-224, 2021.
3. Matano Y, Nojiri Y, Nomura M, Masuda A, Moriike Y, Suzuki Y, Umemura K, Nagai N. Repair of brain damage size and recovery of neurological dysfunction after ischemic stroke are different between strains in mice: Evaluation using a novel ischemic stroke model. Experimental Animals. 70 (3): 344-354. 2021.
4. 鈴木康裕、松野香里、稲野彰洋。抗体医薬品のマイクロドーズ量に関する初回投与量と承認された最小臨床用量からの考察。臨床薬理 51 (1), 1-10, 2020.
5. Ono T, Sato K, Shimizu S, Yoshida K, Dairaku T, Suzuki Y, Kashiwagi Y. Electrocatalytic Oxidation of Carbohydrates Mediated by Nitroxyl Radical-modified Electrodes in Aqueous Solution. Electroanalysis 30 (1), 24-26, 2018.
6. Ohmori C, Sakai Y, Matano Y, Suzuki Y, Umemura K, Nagai N. Increase in blood-brain barrier permeability dose not directly induce neuronal neuronal death but may accelerate ischemic neuronal damage. Exp. Anim. 67 (4), 479-486, 2018.
7. Suzuki Y, Nagai N, Yamakawa K, Muranaka Y, Hokamura K, Umemura K, Recombinant tissue-type plasminogen activator transiently enhances blood-brain barrier permeability during cerebral ischemia through vascular endothelial growth factor-mediated endothelial endocytosis in mice. J Cereb Blood Flow Metab.35(12):2021-31.2015
8. Harada K, Suzuki Y, Yamakawa K, Kawakami J, Umemura K. Edaravone completely inhibits gelatinase B production increased by the combination of tissue-type plasminogen activator and reactive oxygen species in the brain endothelial cells. Int. J. Neurosci. 122 (2), 53-59, 2012.
9. Kawao N, Nagai N, Tmura Y, Horiuchi Y, Okumoto K, Okada K, Yano M, Ueshima S, Suzuki Y, Umemura K, Matsuo O. Urokinase-type plasminogen activator and plasminogen mediate activation of macrophages phagocytosis during liver repair in vivo. Thromb. Haemost. 107 (4), 749-759, 2012.
10. Kawao N, Nagai N, Tamura Y, Okada K, Yano M, Suzuki Y, Umemura K, Ueshima S, Matsuo O. Urokinase-type plasminogen activator contributes to heterogeneity of macrophages at the border of damaged site during liver repair in mice. Thromb. Haemost. 105 (5), 892-900, 2011.

総説

1. 鈴木康裕*、t-PAのBBB透過性亢進のメカニズムに迫ってきた各種動物実験、日本血栓止血学会誌、2018、29(5)、P461-464.
2. Suzuki Y*, Nagai N, Umemura K. A review of the mechanisms of blood-brain barrier permeability by tissue-type plasminogen activator treatment for cerebral ischemia. Frontiers in Cellular Neuroscience. 2016, 10: 2.
3. Suzuki Y*, Evaluation for antithrombotic agents by a thrombotic model in animals. (血栓動物病態モデルによる抗血栓薬の評価) Yakugaku-Zasshi, 132 (9), 1019-1024, 2012.
4. Suzuki Y*, Nagai N, Umemura K. Intracranial bleeding associated with the treatment of ischemic stroke: Thrombolytic treatment of ischemia-affected endothelial cells with tissue-type plasminogen activator. Journal of Pharmacological Science, 116 (1), 25-29, 2011.

• 日本薬学会
• 日本医療薬学会
• 日本薬理学会
• 日本臨床薬理学会
• 日本血栓止血学会